New Mutation Identified in Primary Myelofibrosis Patients

Article

In a late-breaking abstract presentation, Thorsten Klampfl, PhD, of the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, presented data from a whole exome study of primary myelofibrosis patients, identifying a new specific molecular mutation

In a late-breaking abstract presentation, Thorsten Klampfl, PhD, of the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, presented data from a whole exome study of primary myelofibrosis patients, identifying a new specific molecular mutation: mutations in exon 9 of the CALR gene. CALR encodes for calreticulin. CALR gene mutations represent a new mutation type not associated with the other frequent mutations among primary myelofibrosis patients: mutations in JAK2 and MPL. Here, Thorsten Klampfl summarizes these results and discusses the implications of the new findings.

Reference: Klampfl T, Gisslinger H, Harutyunyan AS, et al. Frequent mutations in the calreticulin gene CALR in myeloproliferative neoplasms. ASH Annual Meeting Abstracts. 2013; Abstract LBA-1.

Related Videos
Treatment with CAR T cells may allow patients with hematologic malignancies to recover more quickly compared with a transplant, says Andre Goy, MD.
Expert on MF
Experts on MF
In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.
Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center .
Related Content